📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
55 announcements match the current filters (relevance ≥ 5).
Concord Biotech Completes ANVISA Inspection at Limbasi API Facility
Concord Biotech Limited has successfully completed an inspection by the Brazilian Health Regulatory Agency (ANVISA) at its Limbasi API manufacturing facility. The inspection was conducted over five days from June 8 to June 12, 2026. This successful outcome is a key milestone for the company's international expansion, facilitating entry into the large Brazilian pharmaceutical market. It reinforces the company's global regulatory footprint and adherence to high-quality manufacturing standards.
Key Highlights
Successful completion of ANVISA inspection at the Limbasi API manufacturing facility.
Inspection conducted by the Brazilian Health Regulatory Agency from June 8 to June 12, 2026.
Enhances access to the Brazilian pharmaceutical market, one of the largest in the world.
Strengthens the company's global manufacturing and regulatory footprint for its API business.
👀 What to Watch
Investors should view this as a positive regulatory development that paves the way for revenue growth in the Latin American region. Monitor for future product filings and approvals in the Brazilian market following this facility clearance.
Concord Biotech Gets USFDA Approval for Tofacitinib Tablets; Targets $500M US Market
Concord Biotech has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. The drug is indicated for several chronic conditions, including rheumatoid arthritis and ulcerative colitis. The estimated U.S. market size for these specific strengths is approximately $500 million, representing a significant revenue opportunity. This approval is a key milestone in the company's strategy to expand its presence in the U.S. and international pharmaceutical markets.
Key Highlights
Received USFDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths
Addresses a U.S. market opportunity estimated at approximately $500 million
Indicated for treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis
Strengthens the company's product portfolio and long-term growth strategy in the U.S. market
👀 What to Watch
This approval is a significant positive trigger for the stock as it opens up a large addressable market in the U.S. Investors should watch for the commercial launch timeline and subsequent market share gains.
Concord Biotech FY26 PAT Drops 30% to ₹260 Cr; Management Guides for >18% Growth in FY27
Concord Biotech reported a challenging FY26 with total revenue declining 12% to ₹829 crores and PAT falling 30% to ₹260 crores, primarily due to geopolitical headwinds and supply chain disruptions in the Middle East and Europe. Despite the decline, the company maintained a healthy adjusted EBITDA margin of 39% and remains debt-free with ₹414 crores in cash. Management has provided a positive outlook for FY27, expecting growth to exceed their historical 18% average as supply issues normalize and new facilities scale up.
Key Highlights
FY26 Revenue declined 12% YoY to ₹829 crores, with Q4 witnessing a sharper 24% degrowth.
Profit After Tax (PAT) for the full year stood at ₹260 crores, down 30% compared to the previous fiscal.
Adjusted EBITDA margin (excluding new facility expenses) remained strong at 39%, though reported margin was 35%.
Management guides for FY27 growth to be higher than the historical 18% average, supported by a strong H1 visibility.
The company is debt-free with ₹414 crores in cash and has a peak revenue potential of ₹3,000 crores from existing units.
👀 What to Watch
Investors should focus on Q1 FY27 performance to confirm the management's turnaround guidance. While FY26 was impacted by temporary external factors, the company's strong balance sheet and new injectable/US subsidiary platforms provide a base for recovery.
Concord Biotech Secures USFDA Approval for Mycophenolate Mofetil; US Market Size $30 Million
Concord Biotech Limited has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. This immunosuppressant is used to prevent organ rejection in kidney, heart, or liver transplant patients. The U.S. market for this specific product is estimated at approximately US$ 30 million. This approval is a key step in the company's strategy to expand its presence and product offerings in the U.S. and international markets.
Key Highlights
Received USFDA approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
The estimated U.S. market size for this product is approximately US$ 30 million.
Indicated for prophylaxis of organ rejection in adult and pediatric transplant recipients.
Strengthens the company's position in the U.S. market and supports long-term growth strategy.
Approval follows Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should view this as a positive development that adds a new revenue stream in the U.S. market. Monitor the company's execution in capturing market share within this $30 million segment.
Concord Biotech FY26 PAT drops 30% to ₹259 Cr amid global headwinds and procurement delays
Concord Biotech reported a challenging FY26 with consolidated revenue declining 12% YoY to ₹1,054.9 crore and PAT falling 30% to ₹259.2 crore. EBITDA margins saw significant compression, dropping to 34.8% from 42.2% in the previous year, primarily due to geopolitical tensions in the Middle East and a shift in US procurement patterns from bulk to staggered orders. Despite the financial dip, the company successfully commercialized its injectable facility and established a US subsidiary, Stellon Biotech, to strengthen its global footprint.
Key Highlights
Consolidated Revenue for FY26 decreased by 12% YoY to ₹1,054.9 crore compared to ₹1,200.1 crore in FY25.
Full-year EBITDA margin contracted by 736 bps to 34.8%, while Q4FY26 margin stood at 36.4%.
Net Profit (PAT) for the year declined by 30% YoY to ₹259.2 crore from ₹371.6 crore.
API segment remains the primary driver contributing 79% of total revenue, with formulations at 21%.
Management identified specific headwinds including a 3-month delay in EU regulatory confirmations and US Veterans Affairs tender delays.
👀 What to Watch
Investors should exercise caution due to the significant margin contraction and revenue decline, though management's optimism for an FY27 recovery backed by new injectable and soft gel facilities warrants a 'watch' for signs of turnaround in the next two quarters.
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Financial Results
Concord Biotech's Board has recommended a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The company reported audited financial results for both standalone and consolidated entities with an unmodified audit opinion from BSR & Co. LLP. To strengthen governance, the board appointed Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payout is set for July 24, 2026, subject to shareholder approval.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Fixed July 24, 2026, as the record date for identifying shareholders eligible for the dividend payout.
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026.
Statutory auditors issued an unmodified opinion on the standalone and consolidated financial results for FY26.
Appointed Manubhai & Shah LLP and Dalwadi & Associates as Internal and Cost Auditors respectively for FY27.
👀 What to Watch
Investors should ensure they hold the shares by the record date of July 24, 2026, to qualify for the ₹7.55 dividend. The clean audit report and addition of an independent director reflect stable corporate governance.
Concord Biotech Recommends ₹7.55 Dividend; Appoints New Independent Director
Concord Biotech's board has recommended a final dividend of ₹7.55 per share for FY 2025-26, subject to shareholder approval. The company reported audited financial results for the year ended March 31, 2026, receiving a clean, unmodified opinion from its statutory auditors. In a move to strengthen governance, Mrs. Ekta Gupta has been appointed as an Additional Independent Director for a five-year term. The board also finalized the appointment of new internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 each for FY 2025-26
Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend payment
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026
Statutory auditors BSR & Co. LLP issued an unmodified audit opinion for the FY26 financial results
Appointed M/s. Manubhai & Shah LLP as Internal Auditor for the financial year 2026-27
👀 What to Watch
Investors should ensure they hold the stock before the July 24, 2026, record date to be eligible for the ₹7.55 dividend. The clean audit report and board expansion are positive indicators of corporate governance and stability.
Concord Biotech Approves FY26 Results, Recommends ₹7.55 Dividend, Appoints New Director
Concord Biotech has approved its audited financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a dividend of ₹7.55 per equity share (755% of face value), setting July 24, 2026, as the record date. Additionally, Mrs. Ekta Gupta has been appointed as an Independent Director for a five-year term starting June 1, 2026. The company also finalized the appointment of internal and cost auditors for the 2026-27 fiscal year.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Appointed Mrs. Ekta Gupta as Additional Independent Director for a 5-year term effective June 1, 2026.
Approved audited standalone and consolidated financial results for FY26 with an unmodified audit opinion.
Fixed July 24, 2026, as the record date for dividend eligibility.
Appointed M/s. Manubhai & Shah LLP as Internal Auditor and M/s. Dalwadi & Associates as Cost Auditor for FY 2026-27.
👀 What to Watch
Investors should track the record date of July 24, 2026, to be eligible for the ₹7.55 dividend payout. The unmodified audit report and the addition of a seasoned professional to the board reflect strong governance and financial stability.
Concord Biotech Recommends ₹7.55 Final Dividend; Sets Record Date for July 2026
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share for the financial year 2025-26. The board has fixed July 24, 2026, as the record date to determine shareholder eligibility for the payout, pending approval at the upcoming Annual General Meeting. In addition to the dividend, the company reported audited financial results for FY26 with an unmodified audit opinion from BSR & Co. LLP. The board also strengthened its governance by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term.
Key Highlights
Recommended a final dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26
Fixed July 24, 2026, as the record date for identifying eligible shareholders for the dividend
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026
Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for FY26
Approved the appointment of Manubhai & Shah LLP as Internal Auditors and Dalwadi & Associates as Cost Auditors for FY 2026-27
👀 What to Watch
Investors seeking dividend income should ensure they hold shares before the July 24, 2026 record date. The unmodified audit report and board expansion reflect positive corporate governance and financial stability.
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Audited Financial Results
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share (face value ₹1) for the financial year 2025-26, subject to shareholder approval. The Board approved the audited standalone and consolidated financial results for the year ended March 31, 2026, with statutory auditors issuing an unmodified opinion. Additionally, the company strengthened its board by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payment has been fixed as July 24, 2026.
Key Highlights
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.
Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend payment.
Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026.
Statutory auditors BSR & Co. LLP issued an unmodified audit report for both standalone and consolidated results.
Appointed M/s. Manubhai & Shah LLP and M/s. Dalwadi & Associates as Internal and Cost Auditors respectively for FY 2026-27.
👀 What to Watch
Investors should monitor the upcoming AGM for dividend approval and ensure holdings are in place by the July 24, 2026 record date to qualify for the ₹7.55 per share payout.
CONCOR Signs Strategic MOU with PSA Mumbai for Rail-Based Cargo Movement
CONCOR has entered into a Memorandum of Understanding (MOU) with PSA Mumbai, the largest container terminal at JNPA, to enhance rail-based logistics for domestic and EXIM cargo. The partnership aims to leverage CONCOR's extensive network of Inland Container Depots (ICDs) to provide seamless connectivity and improve cargo evacuation from the port. By operating scheduled container train services and optimizing yard space, the collaboration seeks to reduce road congestion and improve turnaround times. This strategic alliance is expected to lower logistics costs and strengthen CONCOR's position in the multimodal transport sector.
Key Highlights
Strategic collaboration with PSA Mumbai, India's largest container terminal at JNPA
Focus on rail-based movement for domestic, cabotage, and customs-cleared EXIM cargo
Integration of PSA Mumbai with CONCOR's nationwide network of ICDs and domestic terminals
Plans to operate scheduled container train services to improve logistics efficiency
Objective to reduce road congestion and improve cargo turnaround times through rail evacuation
👀 What to Watch
Investors should monitor the operational rollout of scheduled train services between PSA Mumbai and CONCOR terminals as it could drive volume growth. This partnership strengthens CONCOR's competitive moat in the EXIM logistics segment.
CONCOR Appoints Vivek Gupta as Director (Finance) & CFO for 5-Year Term
Container Corporation of India (CONCOR) has appointed Shri Vivek Gupta as its new Director (Finance) and Chief Financial Officer (CFO) effective April 21, 2026. Mr. Gupta, a 1997 batch IRAS officer with 32 years of experience, succeeds Shri Harish Chandra in the CFO role. His professional background includes significant financial restructuring, notably saving over Rs. 2,700 crores in refinancing deals during his tenure at DFCCIL. This appointment is for a five-year term as approved by the Ministry of Railways.
Key Highlights
Shri Vivek Gupta appointed as Director (Finance) & CFO for a 5-year term starting April 21, 2026
Appointee is a 1997 Batch IRAS officer with B.Tech from IIT-BHU and MBA from BITS Pilani
Previously saved over Rs. 2,700 crores for the GOI exchequer through World Bank loan refinancing at DFCCIL
Shri Harish Chandra ceases to hold the CFO charge but remains Principal Executive Director & Company Secretary
👀 What to Watch
Investors should view this as a positive leadership transition given Mr. Gupta's extensive experience in railway finance and proven track record in financial optimization. No immediate action is required, but monitor for any strategic shifts in capital allocation.
CONCOR Appoints Vivek Gupta as Director (Finance); Ms. Pallavi Joshi Steps Down
Container Corporation of India (CONCOR) has appointed Shri Vivek Gupta as Director (Finance) for a five-year term effective April 21, 2026. He succeeds Ms. Pallavi Joshi, who was holding the additional charge of the position. Shri Gupta is a 1997 Batch IRAS officer with over 32 years of experience in finance, IT, and business development within the Indian Railways and DFCCIL. His track record includes a significant refinancing deal at DFCCIL that saved the government exchequer over Rs. 2,700 crores.
Key Highlights
Shri Vivek Gupta appointed as Director (Finance) for a 5-year tenure starting April 21, 2026
Ms. Pallavi Joshi ceases to hold the additional charge of Director (Finance) effective April 21, 2026
New appointee has 32+ years of experience, including saving Rs. 2,700 crores via loan refinancing at DFCCIL
Shri Gupta holds a B.Tech from IIT-BHU and an MBA in Finance from BITS Pilani
The appointment was approved by the Ministry of Railways as per the company's Articles of Association
👀 What to Watch
Investors should view this as a positive development given the appointee's extensive experience in railway finance and logistics. Monitor the new Director's impact on CONCOR's capital allocation and cost-efficiency strategies.
CONCOR Appoints Shri Vivek Gupta as Director (Finance) for a 5-Year Term
Container Corporation of India (CONCOR) has announced the appointment of Shri Vivek Gupta as Director (Finance) following approval from the Ministry of Railways. Shri Gupta, an IRAS officer previously serving as GGM/Finance at DFCCIL, will serve a five-year term on an immediate absorption basis. The appointment includes a pay scale of Rs. 1,80,000 - 3,40,000 (IDA). This move fills a critical board-level position responsible for the company's financial strategy and oversight.
Key Highlights
Shri Vivek Gupta appointed as Director (Finance) for a period of 5 years
Appointment approved by Ministry of Railways via order dated April 20, 2026
Pay scale fixed at Rs. 1,80,000 - 3,40,000 under IDA patterns
Shri Gupta joins from DFCCIL where he served as GGM/Finance
👀 What to Watch
This is a routine management transition for a PSU; investors should monitor if the new leadership introduces any changes to capital allocation or dividend policies.
CONCOR Places ₹175.36 Crore Order for 9 Spine Car Rakes with Braithwaite & Co
Container Corporation of India (CONCOR) has awarded a contract worth ₹175.36 crore to Braithwaite & Co Ltd for the manufacture and supply of 9 BLSS (Spine Car) rakes. This order is part of CONCOR's ongoing efforts to expand its rolling stock capacity and enhance its multi-modal logistics services. The delivery is scheduled to be completed by February 28, 2027, with a minimum delivery rate of two rakes per month. This capital expenditure reflects the company's focus on strengthening its infrastructure to handle increasing freight volumes.
Key Highlights
Order value of ₹175.36 Crores (excluding GST) awarded to domestic entity Braithwaite & Co Ltd
Contract involves manufacture and supply of 09 BLSS (Spine Car) rakes on a turnkey basis
Delivery timeline set for completion by February 28, 2027, with a minimum of 2 rakes per month
The transaction is not a related party transaction and involves no promoter interest
👀 What to Watch
Investors should view this as a positive step towards capacity augmentation which supports long-term volume growth. Maintain a focus on the company's ability to improve market share in the rail freight segment.
CONCOR Appoints Ms. Pallavi Joshi as Director (Finance) with Additional Charge
Container Corporation of India (CONCOR) has appointed Ms. Pallavi Joshi, a 2004 batch IRAS officer, as Director (Finance) with additional charge effective April 09, 2026. Ms. Joshi brings over 20 years of experience in financial management within the Indian Railways and previously served as General Manager (Finance) at DFCCIL. Her expertise includes handling infrastructure financing through External Commercial Borrowing (ECB) and World Bank loan refinancing. This appointment ensures continuity in financial leadership under the Ministry of Railways' oversight.
Key Highlights
Ms. Pallavi Joshi appointed as Director (Finance) with additional charge effective April 09, 2026
She is a 2004 batch IRAS officer with over 20 years of experience in railway financial management
Previously managed India's first MIGA-backed ECB infrastructure financing and World Bank loan refinancing at DFCCIL
The appointment follows the Ministry of Railways' order and was approved by the Board on April 10, 2026
👀 What to Watch
No immediate action is required as this is a routine senior management appointment. Investors should monitor for the eventual appointment of a permanent full-time Director (Finance).
CONCOR Reports 9.56% Growth in Total Physical Volumes for FY26
Container Corporation of India (CONCOR) has released its provisional physical volume data for the quarter and year ended March 2026. The company achieved a total throughput of 55.82 lakh TEUs for the full year, representing a 9.56% growth over the previous year. The domestic segment (DOM) was a standout performer, growing by 18.97% in the March quarter and 14.59% for the full year. While EXIM growth was more tempered at 2.22% for the quarter, the overall volume trajectory remains healthy for the logistics major.
Key Highlights
Total annual throughput (PE Mar-26) increased by 9.56% YoY to 55,82,193 TEUs.
Domestic (DOM) volumes for QE Mar-26 grew significantly by 18.97% to 3,59,819 TEUs.
EXIM volumes for the full year rose by 8.02% reaching 42,07,756 TEUs.
Quarterly total throughput (QE Mar-26) stood at 14,28,102 TEUs, up 5.98% YoY.
👀 What to Watch
The robust growth in domestic volumes suggests strong internal demand and market positioning; investors should remain positive on the stock. Monitor the upcoming full financial results to see how these volumes translate into revenue and margin improvements.
Concord Biotech Acquires 100% Stake in Celliimune Biotech for Rs 66 Lakhs
Concord Biotech has completed the 100% acquisition of Celliimune Biotech Private Limited for a cash consideration of Rs 66 lakhs. Celliimune is a biopharmaceutical startup focused on pioneering DNA engineering for cancer therapeutics and cell/gene therapy solutions. While the target entity currently has nil turnover, the acquisition is a strategic move to enter the high-growth oncology research space. This transaction is classified as a related party transaction as the promoter group previously held a majority stake in the target entity.
Key Highlights
Acquisition of 100% equity stake in Celliimune Biotech Private Limited for Rs 66,00,000
Target entity focuses on DNA engineering for cancer therapeutics and cell/gene therapy solutions
Celliimune was incorporated in January 2025 and currently reports nil turnover
Transaction is a related party deal as promoters previously held majority control
Acquisition completed on April 02, 2026, via cash consideration
👀 What to Watch
Investors should view this as a long-term R&D play rather than an immediate revenue driver. Monitor for future updates on clinical breakthroughs or product development from this new subsidiary.
Concord Biotech Q3 Revenue Up 14% YoY to ₹278 Cr; PAT Dips 8.5% on Exceptional Costs
Concord Biotech reported a 13.9% YoY increase in revenue from operations to ₹27,813 lakhs for Q3 FY26. However, Net Profit (PAT) declined by 8.5% YoY to ₹6,778 lakhs, primarily impacted by a one-time exceptional charge of ₹327.54 lakhs related to new labour code regulations. On a sequential basis, the company showed recovery with revenue and PAT growing 12.6% and 7.8% respectively compared to Q2 FY26. The board also strengthened its leadership by appointing Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer.
Key Highlights
Revenue from operations grew 13.9% YoY to ₹27,813.39 lakhs in Q3 FY26 compared to ₹24,422.02 lakhs in Q3 FY25.
Net Profit (PAT) for the quarter stood at ₹6,778.27 lakhs, a decline from ₹7,408.88 lakhs in the corresponding quarter last year.
Recognized an exceptional item of ₹327.54 lakhs due to the statutory impact of new labour codes on employee benefit obligations.
9-month PAT for FY26 shows a significant decline to ₹17,324.46 lakhs from ₹23,102.69 lakhs in the same period last year.
Appointed Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026.
👀 What to Watch
Investors should monitor the margin pressure as PAT has declined despite healthy revenue growth. The significant year-to-date profit lag compared to the previous fiscal suggests a cautious outlook until bottom-line growth stabilizes.
CONCOR Signs MoU with Vizhinjam International Seaport for New Container Freight Station
CONCOR has signed a non-binding Memorandum of Understanding (MoU) with Vizhinjam International Seaport Ltd (VISL) to develop a Container Freight Station (CFS) in Kerala. Under the agreement, VISL will provide the land while both parties will jointly develop infrastructure including customs-bonded areas, warehouses, and container handling yards. This strategic move positions CONCOR at a key upcoming deep-water transshipment hub, enhancing its multimodal logistics capabilities in South India. The collaboration is aimed at improving cargo handling efficiencies and supporting the growth of India's EXIM trade.
Key Highlights
MoU signed on February 23, 2026, for a new CFS near Vizhinjam International Seaport, Thiruvananthapuram.
VISL, a Kerala Government undertaking, will provide land for the project on mutually agreed terms.
The facility will feature customs-bonded areas, warehouses, and specialized import-export cargo handling facilities.
Strategic focus on leveraging Vizhinjam's status as a global maritime gateway for rail-led multimodal logistics.
Both parties will enter a subsequent definitive agreement to frame detailed terms and conditions.
👀 What to Watch
This is a positive development for long-term growth as it secures CONCOR's presence at a critical transshipment hub. Investors should monitor the transition from a non-binding MoU to a definitive agreement for clarity on capital expenditure and timelines.
